Clinical Report: Underestimation of Hyperphagia Severity in Adults with BBS

Overview

This study assesses the reporting of hyperphagia severity in adults with Bardet-Biedl syndrome (BBS) using self-reported questionnaires and semi-structured interviews.

Background

Bardet-Biedl syndrome (BBS) is a rare genetic disorder characterized by symptoms including hyperphagia, which can lead to obesity and health complications. Accurate assessment of hyperphagia severity is crucial for management and treatment of individuals with BBS. This study aims to evaluate the limitations of self-reporting in assessing hyperphagia severity in this population.

Data Highlights

Key Findings

• Hyperphagia was classified as severe in 5.9% of participants using questionnaires.
• In contrast, semi-structured interviews classified hyperphagia as severe in 66.7% of participants.
• 86.7% of participants had a higher severity rating in interviews compared to questionnaires.
• In participants with BMI ≥30 kg/m2, 69.2% were classified as having severe hyperphagia based on interviews.
• The study emphasizes the need for mixed-method approaches to assess hyperphagia in BBS.

Clinical Implications

Healthcare professionals should consider incorporating semi-structured interviews into the assessment of hyperphagia severity in adults with BBS to obtain a more accurate understanding of the condition. This approach may help in tailoring management strategies and treatment options more effectively.

Conclusion

The study reveals discrepancies in hyperphagia severity assessment methods, highlighting the need for comprehensive evaluation techniques in managing Bardet-Biedl syndrome.

Related Resources & Content

1. Bardet-Biedl syndrome improved diagnosis criteria and management: Inter European Reference Networks consensus statement and recommendations | European Journal of Human Genetics
2. Recommendations | Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome | Guidance | NICE
3. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period - PMC
4. The Journal of Clinical Endocrinology & Metabolism — Examining Fiber Supplementation in Prader-Willi Syndrome: Effects on Metabolism and Gut Microbiota Changes
5. Obesity Surgery — Inadequate Weight Loss 13 Years Following Roux-en-Y Gastric Bypass: Are Hedonic Hunger, Eating Patterns, and Food Reward Contributing Factors?
6. Obesity Surgery — Factors Influencing Postprandial Hypoglycemia Following Gastric Bypass Surgery: A Retrospective Case-Control Analysis
7. Obesity Surgery — Long-Term Weight Loss Outcomes 13 Years Post-Roux-en-Y Gastric Bypass: Exploring the Links Between Homeostatic Appetite and Hedonic Hunger
8. Bardet-Biedl syndrome improved diagnosis criteria and management: Inter European Reference Networks consensus statement and recommendations | European Journal of Human Genetics
9. 1 Recommendations | Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome | Guidance | NICE
10. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period - PMC